Patents by Inventor Kimberly Gillis

Kimberly Gillis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR PURIFICATION OF MESSENGER RNA
    Publication number: 20220170061
    Abstract: The present invention provides, among other things, methods for purifying mRNA based on normal flow filtration for therapeutic use.
    Type: Application
    Filed: October 11, 2021
    Publication date: June 2, 2022
    Inventors: Joseph Parella, Kimberly Gillis, Jonathan Abysalh, Travis Jeannotte, Erik Held, Frank DeRosa, Michael Heartlein, Rebecca Powell
  • PROCESS OF PREPARING ICE-BASED LIPID NANOPARTICLES
    Publication number: 20220133631
    Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing an mRNA solution containing low citrate concentration and a lipid solution at an ambient temperature. Thus, the present invention provides an effective, reliable, energy-saving and cost-effective method of encapsulating mRNA into lipid nanoparticles.
    Type: Application
    Filed: October 12, 2021
    Publication date: May 5, 2022
    Inventors: Monic Shah, Travis Jeanotte, Yi Zhang, Shrirang Karve, Kimberly Gillis, Frank DeRosa
  • PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES
    Publication number: 20220110884
    Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing an mRNA solution containing low citrate concentration and a lipid solution at an ambient temperature. Thus, the present invention provides an effective, reliable, energy-saving and cost-effective method of encapsulating mRNA into lipid nanoparticles.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 14, 2022
    Inventors: Shrirang Karve, Travis Jeanotte, Monic Shah, Yi Zhang, Kimberly Gillis, Frank DeRosa
  • Methods for purification of messenger RNA
    Patent number: 11174500
    Abstract: The present invention provides, among other things, methods for purifying mRNA based on normal flow filtration for therapeutic use.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: November 16, 2021
    Assignee: Translate Bio, Inc.
    Inventors: Joseph Parella, Kimberly Gillis, Jonathan Abysalh, Travis Jeannotte, Erik Held, Frank DeRosa, Michael Heartlein, Rebecca Powell
  • METHODS FOR PURIFICATION OF MESSENGER RNA
    Publication number: 20200095571
    Abstract: The present invention provides, among other things, methods for purifying mRNA based on normal flow filtration for therapeutic use.
    Type: Application
    Filed: August 26, 2019
    Publication date: March 26, 2020
    Inventors: Joseph Parella, Kimberly Gillis, Jonathan Abysalh, Travis Jeannotte, Erik Held, Frank DeRosa, Michael Heartlein, Rebecca Powell
  • Nucleic acid microparticles for pulmonary delivery
    Patent number: 8808747
    Abstract: The present disclosure is related to microparticle compositions, in which the microparticles are made of nucleic acids and non-polymeric cations, which are suitable for administration to moist or aqueous target locations (e.g., the lung tissue), where the substantially spherical nucleic acid microparticles release the nucleic acids through dissolution, allowing the released nucleic acids to freely interact with the target cells.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: August 19, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Larry R. Brown, Kimberly A. Gillis, Michael V. Gallo
  • Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
    Patent number: 8389493
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: March 5, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA, University of Pittsburgh—of The Commonwealth System of Higher Education
    Inventors: Larry R. Brown, Nick Giannoukakis, Kimberly A. Gillis, Massimo Trucco
  • MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES
    Publication number: 20110274758
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Application
    Filed: May 9, 2011
    Publication date: November 10, 2011
    Applicants: BAXTER INTERNATIONAL INC., University of Pittsburgh - Of the Commonwealth System of Higher Education, BAXTER HEALTHCARE S.A.
    Inventors: Larry R. Brown, Nick Giannoukakis, Kimberly A. Gillis, Massimo Trucco
  • Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
    Patent number: 7964574
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: June 21, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A., University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Larry R. Brown, Nick Giannoukakis, Kimberly A. Gillis, Massimo Trucco
  • Expression analysis of FKBP54 in the diagnosis and treatment of prostate cancer
    Publication number: 20090062133
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. FKBP markers are provided, wherein changes in the levels of expression of one or more of the FKBP markers is correlated with the presence of prostate cancer.
    Type: Application
    Filed: July 3, 2008
    Publication date: March 5, 2009
    Inventors: Kimberly A. Gillis, Yixian Zhang
  • Nucleic Acid Microparticles for Pulmonary Delivery
    Publication number: 20090017124
    Abstract: The present disclosure is related to microparticle compositions, in which the microparticles are made of nucleic acids and non-polymeric cations, which are suitable for administration to moist or aqueous target locations (e.g., the lung tissue), where the substantially spherical nucleic acid microparticles release the nucleic acids through dissolution, allowing the released nucleic acids to freely interact with the target cells.
    Type: Application
    Filed: April 17, 2008
    Publication date: January 15, 2009
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Larry R. Brown, Kimberly A. Gillis, Michael V. Gallo
  • Expression analysis of FKBP54 in assessing prostate cancer therapy
    Patent number: 7402388
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. FKBP markers are provided, wherein changes in the levels of expression of one or more of the FKBP markers is correlated with the presence of prostate cancer.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: July 22, 2008
    Assignee: Wyeth
    Inventors: Kimberly A. Gillis, Yixian Zhang
  • MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES
    Publication number: 20080039369
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 14, 2008
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Larry Brown, Nick Giannoukakis, Kimberly Gillis
  • Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
    Patent number: 7037652
    Abstract: The invention relates to methods for detecting, characterizing, preventing, and treating prostate cancer. KIAA markers are provided, wherein changes in the levels of expression of one or more of the KIAA markers is correlated with the presence of prostate cancer.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: May 2, 2006
    Assignee: Wyeth
    Inventors: Kimberly A. Gillis, Yixian Zhang
  • Textile substrates for image printing
    Publication number: 20050235436
    Abstract: A textile coated with a coating having cationic and repellant properties, thereby accepting an image thereon more readily.
    Type: Application
    Filed: June 8, 2005
    Publication date: October 27, 2005
    Inventors: Kirkland Vogt, Kimberly Gillis, Daniel McBride, John Soltis, William Sims
  • Expression analysis of FKBP54 in the diagnosis and treatment of prostate cancer
    Publication number: 20050069946
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. FKBP markers are provided, wherein changes in the levels of expression of one or more of the FKBP markers is correlated with the presence of prostate cancer.
    Type: Application
    Filed: November 23, 2004
    Publication date: March 31, 2005
    Inventors: Kimberly Gillis, Yixian Zhang
  • Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
    Patent number: 6821731
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. FKBP markers are provided, wherein changes in the levels of expression of one or more of the FKBP markers is correlated with the presence of prostate cancer.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: November 23, 2004
    Assignee: Wyeth
    Inventors: Kimberly A. Gillis, Yixian Zhang
  • Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
    Publication number: 20020182614
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. ID markers are provided, wherein changes in the levels of expression of one or more of the ID markers is correlated with the presence of prostate cancer.
    Type: Application
    Filed: November 28, 2001
    Publication date: December 5, 2002
    Inventors: Kimberly A. Gillis, Yixian Zhang
  • Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
    Publication number: 20020168650
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. FKBP markers are provided, wherein changes in the levels of expression of one or more of the FKBP markers is correlated with the presence of prostate cancer.
    Type: Application
    Filed: November 28, 2001
    Publication date: November 14, 2002
    Inventors: Kimberly A. Gillis, Yixian Zhang
  • Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
    Publication number: 20020142327
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. SWI/SNF-related matrix-associated actin-dependent regulator of chromatin (SMARC) markers are provided, wherein changes in the levels of expression of one or more of the SMARC markers is correlated with the presence of prostate cancer.
    Type: Application
    Filed: November 28, 2001
    Publication date: October 3, 2002
    Inventors: Kimberly A. Gillis, Yixian Zhang